7.70
price down icon2.65%   -0.21
after-market Handel nachbörslich: 7.65 -0.05 -0.65%
loading
Schlusskurs vom Vortag:
$7.91
Offen:
$7.88
24-Stunden-Volumen:
615.48K
Relative Volume:
0.91
Marktkapitalisierung:
$14.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-5.73M
KGV:
-1.1756
EPS:
-6.55
Netto-Cashflow:
$-4.13M
1W Leistung:
+53.01%
1M Leistung:
+55.24%
6M Leistung:
+53.69%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$7.46
$8.10
1-Wochen-Bereich:
Value
$4.92
$9.50
52-Wochen-Spanne:
Value
$1.62
$29.28

Dogwood Therapeutics Inc Stock (DWTX) Company Profile

Name
Firmenname
Dogwood Therapeutics Inc
Name
Telefon
(866) 620-8655
Name
Adresse
44 MILTON AVENUE, ALPHARETTA
Name
Mitarbeiter
12
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
DWTX's Discussions on Twitter

Vergleichen Sie DWTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
DWTX
Dogwood Therapeutics Inc
7.70 15.12M 0 -5.73M -4.13M -6.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
391.64 101.35B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.00 58.66B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
562.27 59.43B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
737.56 44.01B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.70 36.56B 3.81B -644.79M -669.77M -6.24

Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten

pulisher
Sep 30, 2025

Dogwood Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com

Sep 30, 2025
pulisher
Sep 30, 2025

What data driven models say about Dogwood Therapeutics Inc.’s futureEarnings Recap Report & Fast Gain Stock Trading Tips - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Is this a good reentry point in Dogwood Therapeutics Inc.July 2025 PostEarnings & Weekly Chart Analysis and Guides - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Using RSI to spot recovery in Dogwood Therapeutics Inc.Quarterly Market Summary & Risk Controlled Daily Trade Plans - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Will Dogwood Therapeutics Inc. stock reach all time highs in 2025Weekly Loss Report & Weekly Hot Stock Watchlists - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Will Dogwood Therapeutics Inc. price bounce be sustainable2025 Trade Ideas & Smart Swing Trading Techniques - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics, Inc. (DWTX) Stock: Skyrockets as NCI-Backed SP16 Deal Sparks Investor Confidence - parameter.io

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug - Stocktwits

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics stock soars after securing cancer pain treatment license - Investing.com UK

Sep 29, 2025
pulisher
Sep 29, 2025

DWTX Stock Surge: Must-Know Insights - StocksToTrade

Sep 29, 2025
pulisher
Sep 29, 2025

How high can Dogwood Therapeutics Inc. stock goPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics Stock Skyrockets: Too Late to Buy? - timothysykes.com

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics : Corporate Presentation (Investor Meeting Presentation Sept 29 2025) - MarketScreener

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics Secures Licensing Deal with Serpin Pharma - TipRanks

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics licenses SP16 for chemotherapy neuropathy treatment - Investing.com India

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics licenses SP16 for chemotherapy neuropathy treatment By Investing.com - Investing.com Australia

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer P - GlobeNewswire

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics Incsecures royalty-free license for Sp16 in all-stock deal with Serpin Pharma - MarketScreener

Sep 29, 2025
pulisher
Sep 29, 2025

Detecting price anomalies in Dogwood Therapeutics Inc. with AIPortfolio Return Report & Verified High Yield Trade Plans - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty - GlobeNewswire

Sep 29, 2025
pulisher
Sep 29, 2025

NCI-Backed First-in-Class Cancer Pain Drug: Dogwood Therapeutics Lands Global Rights to SP16 Treatment - Stock Titan

Sep 29, 2025
pulisher
Sep 29, 2025

Will Dogwood Therapeutics Inc. stock benefit from sector rotationJuly 2025 Big Picture & Expert Curated Trade Setup Alerts - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

Is Dogwood Therapeutics Inc a good long term investmentSector ETF Performance & High Return Investment Plans - earlytimes.in

Sep 28, 2025
pulisher
Sep 27, 2025

What drives Dogwood Therapeutics Inc stock priceStochastic Oscillator Alerts & Superior Trading Portfolio - earlytimes.in

Sep 27, 2025
pulisher
Sep 27, 2025

Dogwood Therapeutics Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Fast Profit Trading Tips - Early Times

Sep 27, 2025

Finanzdaten der Dogwood Therapeutics Inc-Aktie (DWTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.66
price down icon 2.36%
$84.81
price up icon 1.10%
$30.67
price up icon 4.57%
$98.62
price up icon 0.53%
$144.01
price up icon 1.67%
biotechnology ONC
$340.70
price up icon 2.36%
Kapitalisierung:     |  Volumen (24h):